NFE2L2は,HO1/フェリチン経路を活性化することによって,ソラフェニブ誘発のフェロプトーシスと心臓毒性から保護する
Hui Jiang1, Yan Su2, Yinglong Hou3
1Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, China; Department of Pediatrics, The Second Hospital of Shandong University, Jinan, Shandong 250012, China.
Toxicology and applied pharmacology
|August 30, 2025
まとめ
転写因子NFE2L2は,HO-1/フェリチン経路を活性化することによって,ソラフェニブ誘発の心臓毒性から保護し,薬物誘発の心臓損傷を軽減するための新しい治療戦略を提供します.
科学分野:
- 心臓病科
- 分子生物学
- 薬理学について
背景:
- ソラフェニブは有効な癌治療法ですが,心臓に毒性があります.
- NFE2L2は転写因子で,細胞のストレスと鉄のバランスを調節する.
- フェロプトーシスという細胞死経路は 薬物による心臓損傷に関与しています
研究 の 目的:
- ソラフェニブ誘発の心臓毒性におけるNFE2L2の役割を調査する.
- NFE2L2の保護効果の基礎にある分子メカニズムを解明する.
- より安全なソラフェニブ治療のためのNFE2L2を標的とした治療戦略を探求する.
主な方法:
- ソラフェニブで治療された心筋細胞のNFE2L2発現を調べた.
- フェロプトーシス阻害剤 (Fer-1, DFO) とNFE2L2ノックダウン/アゴニスト (SFN) を使用した.
- 分析された脂質過酸化,活性酸素種 (ROS),HO-1/フェリチン軸.
- 試験されたNFE2L2活性化経路 (ERストレス,EIF2AK3)
- ソラフェニブ誘発の心臓毒性に対するSFN in vivoの有効性を評価した.
主要な成果:
- ソラフェニブは,フェロプトーシスに関連した心筋細胞のNFE2L2発現を増加させる.
- NFE2L2のノックダウンにより,ソラフェニブ誘発フェロプトーシス (脂質過酸化の増加,ROS) が悪化する.
- NFE2L2はHO-1/フェリチン軸を活性化し,酸化ストレスを軽減し,鉄のホメオスタシスを促進します.
- ソラフェニブはKEAP1経路ではなく,ERストレス (EIF2AK3) 経由でNFE2L2を活性化します.
- SFN治療は,ソラフェニブ誘発のフェロプトーシスと心臓毒性を in vivoで軽減した.
結論:
- NFE2L2は,ソラフェニブ誘発の心臓毒性に対する重要な保護的役割を果たします.
- NFE2L2-HO-1/フェリチン軸は,フェロプトーシスと酸化ストレスを軽減する重要なメカニズムです.
- ERのストレス依存のNFE2L2活性化は新しい治療目標を提供します.
- SFNのようなNFE2L2アゴニストは,ソラフェニブの安全性を高める有望な戦略です.
関連する概念動画
Necrosis
4.8K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.8K
NF-κB-dependent Signaling Pathway
7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.8K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
The Early Endosome: Endocytosis of Transferrin
3.4K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


